Prot #X16042: A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients with MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen

Project: Research project

StatusActive
Effective start/end date6/1/156/1/21

Funding

  • Millennium Pharmaceuticals, Inc (Prot #X16042)